GILD's long delay in bringing TAF to market was, of course, motivated by the business exigency of launching TAF-based regimens close to the time when the patent on Viread was due to expire.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.